Mobile Clinic Revolutionizes Prostate Cancer Screening

A doctor's gloved hand placing red blocks with health symbols on a table

A urologist in New York quietly screened over 10,000 men for prostate cancer from a mobile unit on wheels, targeting communities where men are twice as likely to die from the disease but half as likely to see a doctor about it.

Story Snapshot

Dr. Ash Tewari launched a mobile prostate screening unit in 2022, funded by billionaire philanthropist Robert F. Smith, delivering free PSA tests and exams across underserved New York neighborhoods.
The program has screened more than 10,000 men, focusing on Black men over 45 and other high-risk groups who face double the mortality rates but significant access barriers.
Early detection through mobile screening boosts five-year survival rates to 99 percent, saving healthcare systems tens of thousands per avoided advanced case.
The initiative reflects a national trend of mobile and free prostate cancer programs emerging post-pandemic to combat screening drops of 30 to 50 percent in vulnerable populations.

When Healthcare Comes to You

Dr. Ash Tewari drives a mobile medical fortress through New York City boroughs, bringing state-of-the-art imaging equipment and blood tests to men who would otherwise never walk into a clinic. The Mount Sinai Health System urologist leads the Robert F. Smith Mobile Prostate Cancer Screening Unit, a facility on wheels that eliminates every excuse standing between high-risk men and potentially life-saving screenings. Since 2022, this rolling clinic has delivered over 10,000 free prostate-specific antigen tests and digital rectal exams to communities where prostate cancer kills at rates nearly double the national average. The concept sounds simple until you consider the logistics: coordinating medical staff, advanced imaging technology, and community outreach while navigating the same traffic jams as food trucks.

The Inequality Behind the Innovation

Black men face prostate cancer incidence and mortality rates between 1.7 and 2.1 times higher than their white counterparts, according to American Cancer Society data. The reasons compound like interest on a bad loan: limited healthcare access, lack of insurance, cultural distrust of medical institutions, and simple geography. Tewari’s mobile unit targets men over 45 in Black communities and men over 55 generally, following American Urological Association guidelines that recognize these elevated risks. The screening debates of the 2010s, when federal guidelines discouraged routine PSA testing over overdiagnosis concerns, created confusion that still haunts underserved populations. By 2017, recommendations shifted to shared decision-making, but the damage lingered in communities already skeptical of preventive care.

Philanthropy Meets Public Health Crisis

Robert F. Smith, the Vista Equity Partners CEO and philanthropist, funded the mobile unit’s launch as part of his broader commitment to addressing health inequities in Black communities. His donation equipped the rolling clinic with technology that rivals stationary facilities, transforming what could have been a publicity stunt into a scalable model for community healthcare. The pandemic had slashed prostate screenings by 30 to 50 percent in some demographics, according to CDC tracking, creating a ticking time bomb of undetected cancers. Smith’s funding arrived precisely when healthcare systems faced the twin pressures of delayed diagnoses and strained resources.

The National Movement Behind the Mobile Unit

Tewari’s initiative joins a constellation of free screening programs across the country. Stony Brook University Hospital offers year-round free screenings. The Cancer Institute of New Jersey at Robert Wood Johnson University Hospital has screened 3,000 men over six years, reaching 700 uninsured patients annually. George Washington University Cancer Center runs monthly events. New Jersey’s CEED program screened 69 men through traveling services in 2023 and 2024. These programs share common DNA: they target the uninsured, remove cost barriers, and bring services to communities rather than waiting for communities to come to them. Dr. Thomas L. Jang at the Cancer Institute of New Jersey framed the mission clearly: detect harmful cancers at a curable stage, especially for men who lack insurance or regular healthcare access.

Economics of Prevention Versus Treatment

Early prostate cancer detection through programs like Tewari’s generates healthcare savings between ten thousand and one hundred thousand dollars per advanced case avoided. Treatment costs escalate dramatically once cancer progresses beyond localized stages, requiring radiation, chemotherapy, hormone therapy, or complex surgeries. The mobile unit’s operating costs, covered entirely by philanthropic funding, shift the financial burden away from public healthcare systems and individual patients. This model aligns with fiscal conservatism’s emphasis on preventive investment over crisis management. When survival rates hit 99 percent with early detection, the math becomes undeniable: spending on screenings today prevents catastrophic spending on late-stage treatment tomorrow. The roughly 10,000 screenings conducted by Tewari’s unit represent potential hundreds of lives extended and millions in treatment costs avoided.

The Clinic That Goes Where It Is Needed Most

Tewari emphasizes the unit’s mobility as its core advantage, bringing screenings to communities that need them most rather than expecting those communities to navigate transportation, work schedules, and bureaucratic intake processes. The mobile approach reduces no-show rates that plague stationary clinics in underserved areas, where a missed bus or an inflexible boss can derail healthcare appointments. Mount Sinai’s ongoing operations continue serving men aged 45 to 79, scheduling appointments through standard hospital channels while maintaining the flexibility to deploy to specific neighborhoods based on need and community partnerships. The model proves scalable, inspiring similar initiatives at other medical centers and potentially reshaping how urban healthcare systems think about access and equity in specialized screening services.